Skip to content

COLESTYRAMINE

DRUG6 trials

Sponsors

Sanofi-Aventis Research & Development, Sanofi-Aventis Recherche & Developpement, Novartis Pharma AG

Conditions

Multiple SclerosisNervous system diseasesmultiple sclerosis

Phase 3

An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
WithdrawnCTIS2023-503631-18-00
Sanofi-Aventis Research & DevelopmentNervous system diseases
Target: 75Updated: 2023-11-27
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
RecruitingCTIS2023-504358-36-00
Sanofi-Aventis Recherche & Developpementmultiple sclerosis
Start: 2024-10-17Target: 386Updated: 2026-01-10
An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
Active, not recruitingCTIS2023-503631-18-01
Sanofi-Aventis Recherche & DeveloppementNervous system diseases
Start: 2024-05-20Target: 1405Updated: 2025-11-11
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Active, not recruitingCTIS2023-509345-12-00
Novartis Pharma AGMultiple Sclerosis
Start: 2022-06-22Target: 464Updated: 2026-01-08
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Active, not recruitingCTIS2023-509372-41-00
Novartis Pharma AGMultiple Sclerosis
Start: 2022-01-30Target: 563Updated: 2026-01-26
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
RecruitingCTIS2024-514343-29-00
Sanofi-Aventis Recherche & Developpementmultiple sclerosis
Start: 2024-11-19Target: 410Updated: 2026-01-10